Boswellia, 5-LOXIN®, bij osteoartrose en reumapijn
In a recent human study, both 100mg and 250mg of 5-LOXIN daily provided improvement in joint comfort and mobility within 7 days
- 5-LOXIN provided significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health
- 5-LOXIN positively impacted biological markers associated with joint and general health, including TNFa, CRP, and IL-6
- 5-LOXIN was shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues
- 5-LOXIN is well-tolerated, easy on the stomach and supported by extensive safety data   
 Spitzner JR1, Chung IK, Muller MT. | Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. | Nucleic Acids Res. | 1990 Jan 11;18(1):1-11.
 Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, Dey D, Raychaudhuri SP. | A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. | Arthritis Res Ther. | 2008;10(4):R85. doi: 10.1186/ar2461. Epub 2008 Jul 30.
 Quan F1, Forte MA. | Two forms of Drosophila melanogaster Gs alpha are produced by alternate splicing involving an unusual splice site. | Mol Cell Biol. | 1990 Mar;10(3):910-7.